WO2007129111A1 - Diazepine derivatives as 5-ht2a antagonists - Google Patents
Diazepine derivatives as 5-ht2a antagonists Download PDFInfo
- Publication number
- WO2007129111A1 WO2007129111A1 PCT/GB2007/050224 GB2007050224W WO2007129111A1 WO 2007129111 A1 WO2007129111 A1 WO 2007129111A1 GB 2007050224 W GB2007050224 W GB 2007050224W WO 2007129111 A1 WO2007129111 A1 WO 2007129111A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound according
- carbon atoms
- pharmaceutically acceptable
- compounds
- formula
- Prior art date
Links
- 0 CPC(*)=CC(CCNN)=O Chemical compound CPC(*)=CC(CCNN)=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Definitions
- the present invention relates to a class of diazepine derivatives which act on serotonin receptors (also known as 5-hydroxytryptamine or 5 -HT receptors). More particularly, the invention concerns a class of 5-amino-7-aryl-2,3-dihydro- IH- 1 ,4-diazepines and benzo-fused analogues thereof. These compounds are potent and selective antagonists of the human 5-HT 2 A receptor and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of adverse conditions of the central nervous system, including sleep disorders such as insomnia, psychotic disorders such as schizophrenia and psychiatric disorders such as anxiety.
- sleep disorders such as insomnia
- psychotic disorders such as schizophrenia and psychiatric disorders such as anxiety.
- Compounds of the invention typically display more effective binding to the human 5-HT 2 A receptor than to other human receptors such as D 2 and IKr receptors. They can therefore be expected to manifest fewer side-effects than compounds which do not discriminate in their binding affinity between such receptors. In particular these compounds have lower effects on the IKr receptors and there is a separation of the desired effect from side effects such as cardiac effects.
- the compounds of the present invention are effective in the treatment of neurological conditions including sleep disorders such as insomnia, psychotic disorders such as schizophrenia, and also depression, anxiety, panic disorder, obsessive-compulsive disorder, pain, eating disorders such as anorexia nervosa, and dependency or acute toxicity associated with narcotic agents such as LSD or MDMA; and moreover are beneficial in controlling the extrapyramidal symptoms associated with the administration of neuroleptic agents. They are also effective in the lowering of intraocular pressure and hence in treating glaucoma, and may also be effective in treating menopausal symptoms, in particular hot flushes (see Waldinger et al, Maturitas, 2000, 36, 165-8).
- 5-HT 2A receptor antagonists many containing inter alia a sulphonyl moiety as described in WO 2005/047246, WO 2005/047247, WO 03/099786, WO 2004/101518, WO 01/74797, WO 00/43362, WO 96/35666, EP-A- 0261688, EP-0304888, and US Patents 4,218,455 and 4,128,552, DE-A-3901735 and Fletcher et al, J. Med. Chem., 2002, 45, 492-503. None of these publications, however, discloses or suggests the class of compounds provided by the present invention.
- US 4,096,140 discloses certain 5-amino-7-aryl-2,3-dihydro-lH-l,4-diazepines as anti- obesity or anti-diabetic agents, but there is no disclosure of activity towards the 5-HT 2A receptor or of utility in treating conditions known to be mediated by 5-HT 2A receptor activity.
- the compounds according to the present invention are potent and selective 5-HT 2A receptor antagonists, suitably having a human 5-HT 2A receptor binding affinity (K 1 ) of 1000 nM or less, typically of 500 nM or less and preferably of 100 nM or less.
- K 1 human 5-HT 2A receptor binding affinity
- the compounds of the invention may possess at least a 10-fold selective affinity, suitably at least a 20-fold selective affinity and preferably at least a 50-fold selective affinity, for the human 5-HT 2A receptor relative to the human dopamine D 2 receptor and/or the human IKr receptors. Many compounds also show selectivity relative to the human 5-HT 2c receptor.
- each A represents CR 2 where each R is independently H or or the moiety A-A represents 1 ,2-phenylene;
- Ar represents phenyl or pyridyl which bears 0 - 3 substituents selected from halogen, Ci- 4alkyl, CN and CF 3 ;
- R 1 represents a hydrocarbon group of up to 12 carbon atoms.
- the invention further provides a method of treatment of a subject suffering from or prone to a condition mediated by 5-HT 2A receptor activity which comprises administering to that subject an effective amount of a compound according to formula I or a pharmaceutically acceptable salt thereof.
- the condition mediated by 5-HT 2A receptor activity is sleep disorder, in particular insomnia.
- the condition mediated by 5- HT 2 A receptor activity is selected from psychotic disorders (such as schizophrenia), depression, anxiety, panic disorder, obsessive-compulsive disorder, pain, glaucoma, eating disorders (such as anorexia nervosa), dependency or acute toxicity associated with narcotic agents such as LSD or MDMA, and hot flushes associated with the menopause.
- hydrocarbon group refers to groups consisting solely of carbon and hydrogen atoms. Such groups may comprise linear, branched or cyclic structures, singly or in any combination consistent with the indicated maximum number of carbon atoms, and may be saturated or unsaturated, including aromatic when the indicated maximum number of carbon atoms so permits unless otherwise indicated.
- Ci_ x alkyl where x is an integer greater than 1 refers to straight-chained and branched alkyl groups wherein the number of constituent carbon atoms is in the range 1 to x. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl and t-butyl. Derived expressions such as are to be construed in an analogous manner.
- halogen as used herein includes fluorine, chlorine, bromine and iodine, of which fluorine and chlorine are preferred and fluorine particularly preferred.
- C3-6cycloalkyl refers to nonaromatic monocyclic hydrocarbon ring systems comprising from 3 to 6 ring atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cyclohexenyl.
- the compounds of formula I may be in the form of pharmaceutically acceptable salts.
- Other salts may, however, be useful in the preparation of the compounds of formula I or of their pharmaceutically acceptable salts.
- Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, benzenesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
- a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, benzenesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tart
- the compounds according to the invention may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centres, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.
- each A in formula I represents CR 2 where each R is independently H or Ci- 4 alkyl (such as methyl).
- the moiety A - A represents 1,2- phenylene (i.e. A - A completes a fused benzene ring).
- a - A represents CH 2 -CH 2 or 1 ,2-phenylene, most suitably CH 2 -CH 2 .
- Ar represents phenyl or pyridyl which optionally bears up to 3 substituents selected from halogen, CN and CF 3 .
- Ar represents optionally substituted phenyl.
- Ar bears not more than 2 substituents.
- Preferred substituents include halogen (especially Cl and F) and (such as methyl).
- groups represented by Ar include phenyl, 4-methoxyphenyl, 2-methylphenyl, 4-methylphenyl, 2,4- dimethylphenyl, 3-(trifluoromethyl)phenyl, 2-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 2-fluoro-4-methylphenyl, 2-chlorophenyl, 4-chlorophenyl, 4-cyanophenyl and 2-pyridyl.
- R 1 represents a hydrocarbon group of up to 12 carbon atoms, preferably of 3 to 10 carbon atoms.
- Suitable hydrocarbon groups include alkyl groups, in particular branched alkyl groups such as t-butyl, 2,2-dimethylpropyl, 3-methyl-3-pentyl, 3-ethyl-3-pentyl and 2,3-dimethyl-2-butyl; cycloalkyl groups such as cyclohexyl; alkylcycloalkyl groups such as 1-methylcyclohexyl and 1- ethylcyclopentyl; cycloalkylalkyl groups such as 2-cyclobutyl-2-propyl; and arylalkyl groups such as benzyl, 2-phenylethyl and 2-methyl-3-phenyl-2-propyl.
- R 11 has the same definition and particular identities as described for R 1 with the proviso that if R 11 represents an alkyl group said alkyl group is branched and comprises at least 5 carbon atoms;
- compositions comprising one or more compounds of formula II or pharmaceutically acceptable salts or hydrates thereof and a pharmaceutically acceptable carrier.
- the present invention also provides a compound of formula II or a pharmaceutically acceptable salt or hydrate thereof for use in a method of treatment of the human body.
- the treatment is for a condition mediated by 5-HT 2 A receptor activity.
- Specific compounds useful in this invention include those compounds exemplified hereinafter and their pharmaceutically acceptable salts.
- the compounds of formula I have an activity as antagonists of the human 5-HT 2 A receptor and hence find use in the treatment or prevention of disorders mediated by 5-HT 2A receptor activity.
- compositions comprising one or more compounds of formula I and a pharmaceutically acceptable carrier.
- these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, transdermal patches, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation.
- the principal active ingredient typically is mixed with a pharmaceutical carrier, e.g.
- a tableting ingredient such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate and dicalcium phosphate, or gums, dispersing agents, suspending agents or surfactants such as sorbitan monooleate and polyethylene glycol, and other pharmaceutical diluents, e.g. water, to form a homogeneous preformulation composition containing a compound of the present invention, or a pharmaceutically acceptable salt thereof.
- these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
- This preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention.
- Typical unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the active ingredient.
- Tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
- the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
- suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, poly(ethylene glycol), polyvinylpyrrolidone) or gelatin.
- a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and especially about 0.05 to 5 mg/kg per day.
- the compounds may be administered on a regimen of 1 to 4 times per day but preferably once per day, for example before going to bed.
- the compounds according to this invention may be co-administered with another sleep inducing or anti-schizophrenic or anxiolytic medicament.
- Such co-administration may be desirable where a patient is already established on sleep inducing or anti-schizophrenic or anxiolytic treatment regime involving other conventional medicaments.
- the compounds of the invention may be co-administered with a GABA A receptor agonist such as gaboxadol, or with a short term and/or rapid-onset hypnotic such as Zolpidem, or a benzodiazepine, a barbiturate, a prokineticin modulator, an antihistamine, trazodone, or derivative of trazodone as disclosed in WO 03/068148.
- a GABA A receptor agonist such as gaboxadol
- a short term and/or rapid-onset hypnotic such as Zolpidem, or a benzodiazepine
- a barbiturate such as a benzodiazepine
- a barbiturate such as a benzodiazepine
- a barbiturate such as a benzodiazepine
- a barbiturate such as a benzodiazepine
- a barbiturate such as a benzodiazepin
- a method of treatment or prevention of sleep disorders, schizophrenia or depression comprising administering to a subject in need thereof a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof in combination with gaboxadol.
- the expression "in combination with” requires that therapeutically effective amounts of both a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof and gaboxadol are administered to the subject, but places no restriction on the manner in which this is achieved.
- the two species may be combined in a single dosage form for simultaneous administration to the subject, or may be provided in separate dosage forms for simultaneous or sequential administration to the subject. Sequential administration may be close in time or remote in time, e.g.
- the separate species may be administered at the same frequency or at different frequencies, e.g. one species once a day and the other two or more times a day.
- the separate species may be administered by the same route or by different routes, e.g. one species orally and the other parenterally, although oral administration of both species is preferred, where possible.
- a pharmaceutical composition comprising, in a pharmaceutically acceptable carrier, a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof and gaboxadol.
- the invention further provides the use, for the manufacture of a medicament for treatment or prevention of sleep disorders, schizophrenia or depression, of a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof and gaboxadol.
- the invention further provides a kit comprising a first medicament comprising a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof and a second medicament comprising gaboxadol together with instructions for administering said medicaments sequentially or simultaneously to a patient suffering from a sleep disorder, schizophrenia or depression.
- gaboxadol is inclusive of 4,5,6,7-tetrahydroisoxazolo[5,4- c]pyridin-3-ol in free base or zwitterionic form and also of pharmaceutically acceptable acid addition salts thereof such as the hydrochloride salt. Most suitably, gaboxadol is in the form of a crystalline monohydrate of the zwitterionic form.
- R 1 , Ar and A have the same meanings as before.
- the reaction takes place at ambient temperature using neat reagents.
- Chlorides (1) are available by reaction of POCI3 with lactams (2):
- reaction may be carried out by heating at about 12O 0 C for 12 hours.
- Lactams (2) maybe obtained by cyclisation of enamine derivatives (3) in which R 1 is t- butyl:
- compounds of formula I are conveniently obtained by cyclising compounds (3) under dehydrating conditions, e.g. in the presence of anhydrous CaCl2 (especially when A-A is 1 ,2-phenylene) or of strong acid such as perchloric acid or methanesulfonic acid.
- anhydrous CaCl2 especially when A-A is 1 ,2-phenylene
- strong acid such as perchloric acid or methanesulfonic acid.
- the starting materials and reagents described above may be obtained from commercially available precursors by means of well known synthetic procedures and/or the methods disclosed in the Examples section herein.
- any compound of formula I initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further desired compound of formula I using techniques known from the art.
- a bromo substituent present on Ar may be replaced by cyano by treatment with copper(I) cyanide in the presence of 1- methyl-2-pyrrolidinone (NMP).
- the compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.
- it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991.
- the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
- Step 3 The product of Step 3 (1 mmol) was dissolved in 5 ml of absolute ethanol. The solution was acidified to a pH of about 1 with methanesulfonic acid, refluxed under nitrogen for one hour, allowed to cool to room temperature and evaporated. The residue was purified by preparative TLC to give the target compound.
- the resulting solid was purified by preparative TLC to give the target compound.
- the lactam from Step 1 (1.2 g) was dissolved in 15 ml of POCI3 and heated at 12O 0 C for 12h. The reaction mixture was allowed to cool and the POCI3 was removed at reduced pressure to give the product (1-2 g) in the form of white crystals.
- step 1 The product of step 1 (1.0 mmol) was dissolved in 5 ml of absolute ethanol. 1.0 g of anhydrous CaCl2, was added and the solution was stirred under nitrogen for 24 hours. Solid was filtered off and the filtrate concerntrated. The residue was recrystallized from DCM/ether to give off-red crystals.
Abstract
Compounds of formula I: are selective 5HT2A antagonists and hence find use in treatment or prevention of a variety of CNS disorders.
Description
DIAZEPINE DERIVATIVES AS 5-HT?A ANTAGONISTS
The present invention relates to a class of diazepine derivatives which act on serotonin receptors (also known as 5-hydroxytryptamine or 5 -HT receptors). More particularly, the invention concerns a class of 5-amino-7-aryl-2,3-dihydro- IH- 1 ,4-diazepines and benzo-fused analogues thereof. These compounds are potent and selective antagonists of the human 5-HT2A receptor and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of adverse conditions of the central nervous system, including sleep disorders such as insomnia, psychotic disorders such as schizophrenia and psychiatric disorders such as anxiety. Compounds of the invention typically display more effective binding to the human 5-HT2A receptor than to other human receptors such as D2 and IKr receptors. They can therefore be expected to manifest fewer side-effects than compounds which do not discriminate in their binding affinity between such receptors. In particular these compounds have lower effects on the IKr receptors and there is a separation of the desired effect from side effects such as cardiac effects. By virtue of their potent human 5-HT2A receptor antagonist activity, the compounds of the present invention are effective in the treatment of neurological conditions including sleep disorders such as insomnia, psychotic disorders such as schizophrenia, and also depression, anxiety, panic disorder, obsessive-compulsive disorder, pain, eating disorders such as anorexia nervosa, and dependency or acute toxicity associated with narcotic agents such as LSD or MDMA; and moreover are beneficial in controlling the extrapyramidal symptoms associated with the administration of neuroleptic agents. They are also effective in the lowering of intraocular pressure and hence in treating glaucoma, and may also be effective in treating menopausal symptoms, in particular hot flushes (see Waldinger et al, Maturitas, 2000, 36, 165-8).
Various classes of compounds have been disclosed as 5-HT2A receptor antagonists, many containing inter alia a sulphonyl moiety as described in WO 2005/047246, WO 2005/047247, WO 03/099786, WO 2004/101518, WO 01/74797, WO 00/43362, WO 96/35666, EP-A- 0261688, EP-0304888, and US Patents 4,218,455 and 4,128,552, DE-A-3901735 and Fletcher et al, J. Med. Chem., 2002, 45, 492-503. None of these publications, however, discloses or suggests the class of compounds provided by the present invention. US 4,096,140 discloses certain 5-amino-7-aryl-2,3-dihydro-lH-l,4-diazepines as anti- obesity or anti-diabetic agents, but there is no disclosure of activity towards the 5-HT2A receptor or of utility in treating conditions known to be mediated by 5-HT2A receptor activity.
The compounds according to the present invention are potent and selective 5-HT2A receptor antagonists, suitably having a human 5-HT2A receptor binding affinity (K1) of 1000 nM or less, typically of 500 nM or less and preferably of 100 nM or less. The compounds of the invention may possess at least a 10-fold selective affinity, suitably at least a 20-fold selective affinity and preferably at least a 50-fold selective affinity, for the human 5-HT2A receptor relative
to the human dopamine D2 receptor and/or the human IKr receptors. Many compounds also show selectivity relative to the human 5-HT2c receptor.
According to the invention there is provided the use, for the manufacture of a medicament for treatment or prevention of a condition mediated by 5-HT2A receptor activity, of a compound of formula I:
I or a pharmaceutically acceptable salt or hydrate thereof; wherein each A represents CR2 where each R is independently H or
or the moiety A-A represents 1 ,2-phenylene;
Ar represents phenyl or pyridyl which bears 0 - 3 substituents selected from halogen, Ci- 4alkyl,
CN and CF3; and
R1 represents a hydrocarbon group of up to 12 carbon atoms.
The invention further provides a method of treatment of a subject suffering from or prone to a condition mediated by 5-HT2A receptor activity which comprises administering to that subject an effective amount of a compound according to formula I or a pharmaceutically acceptable salt thereof.
In one aspect of the invention, the condition mediated by 5-HT2A receptor activity is sleep disorder, in particular insomnia. In a further aspect of the invention, the condition mediated by 5- HT2A receptor activity is selected from psychotic disorders (such as schizophrenia), depression, anxiety, panic disorder, obsessive-compulsive disorder, pain, glaucoma, eating disorders (such as anorexia nervosa), dependency or acute toxicity associated with narcotic agents such as LSD or MDMA, and hot flushes associated with the menopause.
Where a variable occurs more than once in formula I or in a substituent group thereof, the individual occurrences of that variable are independent of each other, unless otherwise specified. As used herein, the expression "hydrocarbon group" refers to groups consisting solely of carbon and hydrogen atoms. Such groups may comprise linear, branched or cyclic structures, singly or in any combination consistent with the indicated maximum number of carbon atoms, and may be saturated or unsaturated, including aromatic when the indicated maximum number of carbon atoms so permits unless otherwise indicated.
As used herein, the expression "Ci_xalkyl" where x is an integer greater than 1 refers to straight-chained and branched alkyl groups wherein the number of constituent carbon atoms is in the range 1 to x. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl and t-butyl. Derived expressions such as
are to be construed in an analogous manner.
The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, of which fluorine and chlorine are preferred and fluorine particularly preferred.
The expression "C3-6cycloalkyl" as used herein refers to nonaromatic monocyclic hydrocarbon ring systems comprising from 3 to 6 ring atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cyclohexenyl.
For use in medicine, the compounds of formula I may be in the form of pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds of formula I or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, benzenesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
When the compounds according to the invention have one or more asymmetric centres, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centres, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.
When the compounds of formula I have two or more tautomeric forms, it is to be understood that all such tautomeric forms and mixtures thereof in any proportion are encompassed within the scope of the present invention. For example, the invention extends to the use of tautomers of the compounds of formula I in which the ring nitrogen adjacent to the attachment point OfR1NH is protonated instead of the ring nitrogen adjacent to the attachment point of Ar. In one embodiment, each A in formula I represents CR2 where each R is independently H or Ci-4alkyl (such as methyl). In an alternative embodiment the moiety A - A represents 1,2- phenylene (i.e. A - A completes a fused benzene ring). Typically, A - A represents CH2-CH2 or 1 ,2-phenylene, most suitably CH2-CH2.
Ar represents phenyl or pyridyl which optionally bears up to 3 substituents selected from halogen,
CN and CF3. In a particular embodiment Ar represents optionally substituted phenyl. Typically, Ar bears not more than 2 substituents. Preferred substituents include halogen (especially Cl and F) and
(such as methyl). Specific examples of groups represented by Ar include phenyl, 4-methoxyphenyl, 2-methylphenyl, 4-methylphenyl, 2,4- dimethylphenyl, 3-(trifluoromethyl)phenyl, 2-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 2-fluoro-4-methylphenyl, 2-chlorophenyl, 4-chlorophenyl, 4-cyanophenyl and 2-pyridyl.
R1 represents a hydrocarbon group of up to 12 carbon atoms, preferably of 3 to 10 carbon atoms. Suitable hydrocarbon groups include alkyl groups, in particular branched alkyl groups
such as t-butyl, 2,2-dimethylpropyl, 3-methyl-3-pentyl, 3-ethyl-3-pentyl and 2,3-dimethyl-2-butyl; cycloalkyl groups such as cyclohexyl; alkylcycloalkyl groups such as 1-methylcyclohexyl and 1- ethylcyclopentyl; cycloalkylalkyl groups such as 2-cyclobutyl-2-propyl; and arylalkyl groups such as benzyl, 2-phenylethyl and 2-methyl-3-phenyl-2-propyl.
The invention further extends to compounds of formula II:
R11 has the same definition and particular identities as described for R1 with the proviso that if R11 represents an alkyl group said alkyl group is branched and comprises at least 5 carbon atoms; and
A and Ar have the same definitions and particular identities as before. The invention provides pharmaceutical compositions comprising one or more compounds of formula II or pharmaceutically acceptable salts or hydrates thereof and a pharmaceutically acceptable carrier.
The present invention also provides a compound of formula II or a pharmaceutically acceptable salt or hydrate thereof for use in a method of treatment of the human body. Preferably the treatment is for a condition mediated by 5-HT2A receptor activity.
Specific compounds useful in this invention include those compounds exemplified hereinafter and their pharmaceutically acceptable salts.
The compounds of formula I have an activity as antagonists of the human 5-HT2A receptor and hence find use in the treatment or prevention of disorders mediated by 5-HT2A receptor activity.
The compounds useful in the invention are typically used in the form of pharmaceutical compositions comprising one or more compounds of formula I and a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, transdermal patches, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. The principal active ingredient typically is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate and dicalcium phosphate, or gums, dispersing agents, suspending agents or surfactants such as sorbitan monooleate and polyethylene glycol, and other pharmaceutical diluents, e.g. water, to form a homogeneous preformulation composition containing a compound of the present
invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Typical unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the active ingredient. Tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
The liquid forms in which the compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, liquid- or gel-filled capsules, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil or coconut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, poly(ethylene glycol), polyvinylpyrrolidone) or gelatin.
In the treatment envisaged herein, for example of insomnia or schizophrenia, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and especially about 0.05 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day but preferably once per day, for example before going to bed.
If desired, the compounds according to this invention may be co-administered with another sleep inducing or anti-schizophrenic or anxiolytic medicament. Such co-administration may be desirable where a patient is already established on sleep inducing or anti-schizophrenic or anxiolytic treatment regime involving other conventional medicaments. In particular, for the treatment of sleep disorders, the compounds of the invention may be co-administered with a GABAA receptor agonist such as gaboxadol, or with a short term and/or rapid-onset hypnotic such as Zolpidem, or a benzodiazepine, a barbiturate, a prokineticin modulator, an antihistamine, trazodone, or derivative of trazodone as disclosed in WO 03/068148. According to a further aspect of the invention, there is provided the combination of a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof and gaboxadol for use in treatment or prevention of sleep disorders, schizophrenia or depression.
Also according to the invention, there is provided a method of treatment or prevention of sleep disorders, schizophrenia or depression comprising administering to a subject in need thereof a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof in combination with gaboxadol. As used herein, the expression "in combination with" requires that therapeutically effective amounts of both a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof and gaboxadol are administered to the subject, but places no restriction on the manner in which this is achieved. Thus, the two species may be combined in a single dosage form for simultaneous administration to the subject, or may be provided in separate dosage forms for simultaneous or sequential administration to the subject. Sequential administration may be close in time or remote in time, e.g. one species administered in the morning and the other in the evening. The separate species may be administered at the same frequency or at different frequencies, e.g. one species once a day and the other two or more times a day. The separate species may be administered by the same route or by different routes, e.g. one species orally and the other parenterally, although oral administration of both species is preferred, where possible.
According to a further aspect of the invention there is provided a pharmaceutical composition comprising, in a pharmaceutically acceptable carrier, a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof and gaboxadol.
The invention further provides the use, for the manufacture of a medicament for treatment or prevention of sleep disorders, schizophrenia or depression, of a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof and gaboxadol.
The invention further provides a kit comprising a first medicament comprising a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof and a second medicament comprising gaboxadol together with instructions for administering said medicaments sequentially or simultaneously to a patient suffering from a sleep disorder, schizophrenia or depression.
As used herein, the term "gaboxadol" is inclusive of 4,5,6,7-tetrahydroisoxazolo[5,4- c]pyridin-3-ol in free base or zwitterionic form and also of pharmaceutically acceptable acid addition salts thereof such as the hydrochloride salt. Most suitably, gaboxadol is in the form of a crystalline monohydrate of the zwitterionic form.
Compounds of formula I may be prepared by the methods disclosed in US 4,096,140, or adaptations thereof. Thus, compounds of formula I may be obtained by reacting amines R^-NH2 with chlorides (1):
where R1, Ar and A have the same meanings as before. The reaction takes place at ambient temperature using neat reagents.
Chlorides (1) are available by reaction of POCI3 with lactams (2):
(2) where Ar and A have the same meanings as before. The reaction may be carried out by heating at about 12O0C for 12 hours.
Lactams (2) maybe obtained by cyclisation of enamine derivatives (3) in which R1 is t- butyl:
(3) wherein Ar and A have the same meanings as before. The cyclisation may be effected by refiuxing in xylene for 3 hours.
Alternatively, compounds of formula I are conveniently obtained by cyclising compounds (3) under dehydrating conditions, e.g. in the presence of anhydrous CaCl2 (especially when A-A is 1 ,2-phenylene) or of strong acid such as perchloric acid or methanesulfonic acid.
Details of these processes, and of the preparation of compounds (3), are disclosed in US 4,096,140 and in the Examples section herein.
Where they are not themselves commercially available, the starting materials and reagents described above may be obtained from commercially available precursors by means of well known synthetic procedures and/or the methods disclosed in the Examples section herein.
It will be appreciated that any compound of formula I initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further desired compound of formula I using techniques known from the art. For example, a bromo substituent present on Ar may be replaced by cyano by treatment with copper(I) cyanide in the presence of 1- methyl-2-pyrrolidinone (NMP).
Where the above-described processes for the preparation of the compounds of use in the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers by standard techniques such as preparative HPLC, or the formation of diastereomeric pairs by salt
formation with an optically active acid, such as di-p-toluoyl-D-tartaric acid and/or di-/?-toluoyl-L- tartaric acid, followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
Compounds were tested for their binding to the 5-HT2A receptor and to other receptors such as 5- HT2C and IKr using the methodology described in Fletcher et al, J. Med. Chem., 2002, 45, 492- 503.
EXAMPLES
General Procedure 1
Step l
To a stirred mixture of sodium hydride (60%, 14.6g, 385.4mmol), ethyl formate (43.8g, 730.8mmol), and tetrahydrofuran (300 mL) was added the appropriate acetophenone (182.7 mmol) in tetrahydrofuran (10OmL) at O0C. The reaction mixture was stirred for 2.5 h at room temperature, and then diluted with water (200ml) and washed with ethyl acetate. The aqueous layer was separated and hydroxylamine hydrochloride (12.7g, 182.7 mmol) was added. The mixture was stirred for 17 h at room temperature, and then diluted with 1 N HCl and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and concentrated to give a yellow solid. The crude solid was recrystallized from diethyl ether to give product as a light yellow powder. Yield: 49-55%. Step 2 1
A mixture of the isoxazole from Step 1 (57.5mmol) and the desired alcohol R1OH (60mmol) was stirred in an ice bath, and 0.30 mole of 71% perchloric acid was added dropwise. A white precipitate formed during the addition. When all the acid had been added, the precipitate
gradually thickened as stirring was continued. About 100 mL of water was added. The suspension was stirred until homogeneous, and the solid was filtered. Washing with water, air drying, and washing with dichloromethane left the crude perchlorate salt. Precipitation from 300 ml of acetonitrile with 600 ml of ether gave colorless rods. Yield: 80-90%. Step 3
To ethylenediamine (16 ml, 240 mmol) in 200 ml of methylene chloride was added 48 mmol of the isoxazolium salt from Step 2 in small portions with stirring over a period of 20 minutes. The temperature of the reaction mixture was maintained at 20-300C by cooling and stirring was continued for one hour after the addition of the isoxazolium salt. The reaction mixture was diluted to 500ml by addition of methylene chloride, then extracted twice with 300 ml portions of water and dried over anhydrous magnesium sulfate. The methylene chloride was stripped off at a reduced pressure to obtain an oil. The oil was dissolved in 300 ml of anhydrous ether and filtered free of white solids. The white solids were washed with a small amount of anhydrous ether and the washings were combined with the filtrate. The combined filtrate and washings were evaporated at a reduced pressure to obtain the product (8-12g) as a colorless oil. Step 4
The product of Step 3 (1 mmol) was dissolved in 5 ml of absolute ethanol. The solution was acidified to a pH of about 1 with methanesulfonic acid, refluxed under nitrogen for one hour, allowed to cool to room temperature and evaporated. The residue was purified by preparative TLC to give the target compound.
Examples 1 - 58 The following were prepared by the above method, using the appropriate acetophenone in Step 1 and the appropriate alcohol in Step 2:
(*) - 400 MHz
(**) - Ar = 2-pyridyl
(***) - prepared from 4-bromo analogue as follows:
To 10 ml of anhydrous dimethylformamide was added 150 mg of bromo derivative and 0.3 g of cuprous cyanide, and the mixture heated under reflux for 6 hours. After cooling, a solution of 1 g of ferric chloride and 1 g of 35 percent hydrochloric acid in 10 ml of water was added and stirred for 20 minutes at 60 °C . After cooling to room temperature, the product was extracted twice with
10 ml of CH2CI2. The organic layer was washed with water, followed by removing the CH2CI2.
The resulting solid was purified by preparative TLC to give the target compound.
General Procedure 2
Step l
The product from General Procedure 1, Step 3 (R1 = t-butyl) (33.6mmol) in 100 ml of xylene was refluxed under nitrogen for 3 hours. After 30 minutes crystals began to form. The reaction mixture was allowed to cool to room temperature overnight. The crystals that formed were isolated by filtration, washed with xylene and dried to obtain the product (5-8 g) as white crystals. Step 2
The lactam from Step 1 (1.2 g) was dissolved in 15 ml of POCI3 and heated at 12O0C for 12h. The reaction mixture was allowed to cool and the POCI3 was removed at reduced pressure to give the product (1-2 g) in the form of white crystals.
Step 3
The chloride from Step 2 (100 mg) was dissolved in 0.25 ml of the desired amine R1NH2 and the reaction temperature was maintained at 2O0C for 2h. The amine was removed at reduced pressure to obtain an oil which was then purified by preparative TLC.
Examples 59 - 65
Using General Procedure 2, the following compounds were prepared:
(*) - 300MHz
General Procedure 3
The desired 1 ,2-phenylenediamine (7.5 mmol) was dissolved in 10 ml of methylene chloride and 1 mmol of isoxazolium perchlotate (General Procedure 1, Step 2) was added to the solution. The temperature of the reaction mixture was maintained at O0C by cooling. The reaction mixture was diluted by addition of 20 ml of DCM and then extracted twice with 5 ml portions of water and dried over anhydrous magnesium sulfate. The methylene chloride was stripped off at a reduced pressure to give an oil. The oil was dissolved in 5 ml of anhydrous ether and filtered free of white solids. The white solids were washed with a small amount of anhydrous ether and the washings were combined with the filtrate. The combined filtrate and washings were evaporated at a reduced pressure to obtain the product as a colorless oil (1.2-1.5 g, 50-67%). The crude product was directly used to the next reaction without further purification. Step 2
The product of step 1 (1.0 mmol) was dissolved in 5 ml of absolute ethanol. 1.0 g of anhydrous CaCl2, was added and the solution was stirred under nitrogen for 24 hours. Solid was filtered off and the filtrate concerntrated. The residue was recrystallized from DCM/ether to give off-red crystals.
Example 66
Following General Procedure 3, there was obtained:
1H NMR (300MHz, CD3OD) δ 7.64-7.69 (m, 2H), 7.25-7.28 (m, 2H), 6.86-6.92 (m, 3H), 4.94 (s, IH), 2.29 (s, 3H), 1.55 (s, 9H).
Claims
1. The use, for the manufacture of a medicament for treatment or prevention of a condition mediated by 5-HT2A receptor activity, of a compound of formula I:
I or a pharmaceutically acceptable salt or hydrate thereof; wherein each A represents CR2 where each R is independently H or or the moiety A-A represents 1 ,2-phenylene; Ar represents phenyl or pyridyl which bears 0 - 3 substituents selected from halogen, Ci-
4alkyl, Ci_4alkoxy, CN and CF3; and
R1 represents a hydrocarbon group of up to 12 carbon atoms.
2. Use according to claim 1 wherein said condition is selected from sleep disorders, psychotic disorders (such as schizophrenia), depression, anxiety, panic disorder, obsessive- compulsive disorder, pain, glaucoma, eating disorders (such as anorexia nervosa), dependency or acute toxicity associated with narcotic agents such as LSD or MDMA, and hot flushes associated with the menopause.
3. A compound of formula II:
II or a pharmaceutically acceptable salt or hydrate thereof; wherein A and Ar are as defined in claim 1; and
R11 represents a hydrocarbon group of up to 12 carbon atoms, with the proviso that if R11 represents an alkyl group said alkyl group is branched and comprises at least 5 carbon atoms.
4. A compound according to claim 3 wherein A-A represents CH2-CH2 or 1,2- phenylene.
6. A compound according to any of claims 3-5 wherein R11 is a branched alkyl group comprising 5-12 carbon atoms; or is selected from cycloalkyl groups, cycloalkylalkyl groups, alkylcycloalkyl groups and arylalkyl groups comprising up to 12 carbon atoms.
7. A compound according to claim 6 wherein R11 is selected from:
2,2-dimethylpropyl, 3-methyl-3-pentyl, 3-ethyl-3-pentyl, 2,3-dimethyl-2-butyl, cyclohexyl, 1- methylcyclohexyl, 1-ethylcyclopentyl, 2-cyclobutyl-2-propyl, benzyl, 2-phenylethyl and 2-methyl- 3 -phenyl-2-propyl.
8. A pharmaceutical composition comprising a compound according to any of claims
3-8 and a pharmaceutically acceptable carrier.
9. A compound according to any of claims 3-8 for use in treatment or prevention of a condition mediated by 5-HT2A receptor activity.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0608655.7A GB0608655D0 (en) | 2006-05-03 | 2006-05-03 | Therapeutic Treatment |
GB0608655.7 | 2006-05-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007129111A1 true WO2007129111A1 (en) | 2007-11-15 |
Family
ID=36603774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2007/050224 WO2007129111A1 (en) | 2006-05-03 | 2007-04-30 | Diazepine derivatives as 5-ht2a antagonists |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0608655D0 (en) |
WO (1) | WO2007129111A1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009105507A3 (en) * | 2008-02-19 | 2010-01-14 | Adolor Corporation | Beloxepin, its enantiomers, and analogs thereof for the treatment of pain |
US8148418B2 (en) | 2006-05-18 | 2012-04-03 | Arena Pharmaceuticals, Inc. | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US8148417B2 (en) | 2006-05-18 | 2012-04-03 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US8785441B2 (en) | 2004-11-19 | 2014-07-22 | Arena Pharmaceuticals, Inc. | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US8871797B2 (en) | 2003-07-22 | 2014-10-28 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
US8980891B2 (en) | 2009-12-18 | 2015-03-17 | Arena Pharmaceuticals, Inc. | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US9034911B2 (en) | 2008-10-28 | 2015-05-19 | Arena Pharmaceuticals, Inc. | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
US9199940B2 (en) | 2006-05-18 | 2015-12-01 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor |
US9434692B2 (en) | 2006-10-03 | 2016-09-06 | Arena Pharmaceuticals, Inc. | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US9556149B2 (en) | 2008-04-02 | 2017-01-31 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
US9567327B2 (en) | 2007-08-15 | 2017-02-14 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
US10034859B2 (en) | 2015-07-15 | 2018-07-31 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1494433A (en) * | 1974-03-29 | 1977-12-07 | Sandoz Ltd | Diazepine derivatives |
US4096140A (en) * | 1974-11-29 | 1978-06-20 | Sandoz, Inc. | 5-Amino or substituted amino-7-phenyl or substituted phenyl-2,3-dihydro-1H-1,4-diazepines |
US4315860A (en) * | 1974-03-29 | 1982-02-16 | Sandoz, Inc. | 5-Pyrrolidino, piperidino or N'-2-hydroxyethylpiperazino-7-phenyl or substituted phenyl-2,3-dihydro-1H-1,4-diazepines |
-
2006
- 2006-05-03 GB GBGB0608655.7A patent/GB0608655D0/en not_active Ceased
-
2007
- 2007-04-30 WO PCT/GB2007/050224 patent/WO2007129111A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1494433A (en) * | 1974-03-29 | 1977-12-07 | Sandoz Ltd | Diazepine derivatives |
US4315860A (en) * | 1974-03-29 | 1982-02-16 | Sandoz, Inc. | 5-Pyrrolidino, piperidino or N'-2-hydroxyethylpiperazino-7-phenyl or substituted phenyl-2,3-dihydro-1H-1,4-diazepines |
US4096140A (en) * | 1974-11-29 | 1978-06-20 | Sandoz, Inc. | 5-Amino or substituted amino-7-phenyl or substituted phenyl-2,3-dihydro-1H-1,4-diazepines |
Non-Patent Citations (1)
Title |
---|
SWAIN ET AL: "Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepi nes as 5-HT2A ligands", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 16, no. 23, 7 November 2006 (2006-11-07), pages 6058 - 6062, XP005850601, ISSN: 0960-894X * |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8871797B2 (en) | 2003-07-22 | 2014-10-28 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
US9273035B2 (en) | 2003-07-22 | 2016-03-01 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
US9775829B2 (en) | 2003-07-22 | 2017-10-03 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
US10781180B2 (en) | 2004-11-19 | 2020-09-22 | Arena Pharmaceuticals, Inc. | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US8785441B2 (en) | 2004-11-19 | 2014-07-22 | Arena Pharmaceuticals, Inc. | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US8680119B2 (en) | 2006-05-18 | 2014-03-25 | Arena Pharmaceuticals, Inc. | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US8664258B2 (en) | 2006-05-18 | 2014-03-04 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
USRE45336E1 (en) | 2006-05-18 | 2015-01-13 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
USRE45337E1 (en) | 2006-05-18 | 2015-01-13 | Arena Pharmaceuticals, Inc. | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US9987252B2 (en) | 2006-05-18 | 2018-06-05 | Arena Pharmaceuticals, Inc. | Primary amines and derivitves thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US8148417B2 (en) | 2006-05-18 | 2012-04-03 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US9783502B2 (en) | 2006-05-18 | 2017-10-10 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor |
US9199940B2 (en) | 2006-05-18 | 2015-12-01 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor |
US8148418B2 (en) | 2006-05-18 | 2012-04-03 | Arena Pharmaceuticals, Inc. | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US10351531B2 (en) | 2006-10-03 | 2019-07-16 | Arena Pharmaceuticals, Inc. | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US9434692B2 (en) | 2006-10-03 | 2016-09-06 | Arena Pharmaceuticals, Inc. | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US9732039B2 (en) | 2006-10-03 | 2017-08-15 | Arena Pharmeceuticals, Inc. | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US9567327B2 (en) | 2007-08-15 | 2017-02-14 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US10058549B2 (en) | 2007-08-15 | 2018-08-28 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-α]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
WO2009105507A3 (en) * | 2008-02-19 | 2010-01-14 | Adolor Corporation | Beloxepin, its enantiomers, and analogs thereof for the treatment of pain |
US9556149B2 (en) | 2008-04-02 | 2017-01-31 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
US10787437B2 (en) | 2008-04-02 | 2020-09-29 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
US10543193B2 (en) | 2008-10-28 | 2020-01-28 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
US9353064B2 (en) | 2008-10-28 | 2016-05-31 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
US10071075B2 (en) | 2008-10-28 | 2018-09-11 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
US10117851B2 (en) | 2008-10-28 | 2018-11-06 | Arena Pharmaceuticals, Inc. | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto |
US9034911B2 (en) | 2008-10-28 | 2015-05-19 | Arena Pharmaceuticals, Inc. | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto |
US9745270B2 (en) | 2008-10-28 | 2017-08-29 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
US10583122B2 (en) | 2008-10-28 | 2020-03-10 | Arena Pharmaceuticals, Inc. | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto |
US9801856B2 (en) | 2008-10-28 | 2017-10-31 | Arena Pharmaceuticals, Inc. | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto |
US8980891B2 (en) | 2009-12-18 | 2015-03-17 | Arena Pharmaceuticals, Inc. | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
US10034859B2 (en) | 2015-07-15 | 2018-07-31 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
US11304932B2 (en) | 2015-07-15 | 2022-04-19 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
Also Published As
Publication number | Publication date |
---|---|
GB0608655D0 (en) | 2006-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007129111A1 (en) | Diazepine derivatives as 5-ht2a antagonists | |
EP0170213B1 (en) | Glutarimide antianxiety and antihypertensive agents | |
JPH0570463A (en) | N-acyl-2,3-benzodiazepine derivative, process for producing same, preparation composition containing same and process for producing same | |
AU8713998A (en) | Amide derivative | |
KR100717489B1 (en) | Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same | |
JP2006513201A (en) | 1,5-Diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators | |
CZ277972B6 (en) | BENZOPYRAN(4,3-c)PYRAZOLE OR BENZOTHIOPYRAN(4,3-c)PYRAZOLE DERIVATIVES, PROCESSES OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS IN WHICH THEY ARE COMPRISED | |
US5432192A (en) | Tricyclic compounds and method for treating allergic diseases | |
US5602125A (en) | Thienodiazepine derivatives as cholecystokinin and gastrin antagonists | |
JPH10504820A (en) | Use of N-substituted phenothiazines | |
HUT54151A (en) | Process fopr producing new (r)-(-)-3-quinuclidinone derivatives and pharmaceutical compositions comprising such compounds | |
HU195509B (en) | Process for producing pyridinyl-piperazine derivatives and pharmaceutical compositions containing them as active agents | |
KR20010022658A (en) | 3-Substituted 3,4,5,7-Tetrahydro-Pyrrolo[3',4':4,5]Thieno[2,3-D]Pyrimidine Derivatives, Their Preparation and Use as 5HT Antagonists | |
WO1999038864A1 (en) | Oxazole derivatives as serotonin-1a receptor agonists | |
NZ286340A (en) | Amides of 2-(4-indolyl piperazia-1-yl)-1-ph-enyl (and bemzyl)ethyl amine derivatives with various (cyclo) alkane carboxylic acids; pharmaceutical compositions | |
JPH0586067A (en) | Optically active thienotriazolodiazepine compound | |
IE913005A1 (en) | Indolonaphthyridines | |
US6159981A (en) | 3-substituted pyrido [3',4':4,5] Thieno [2,3-d] pyrimidine derivatives, and production and use of the same | |
JPH04244083A (en) | Tricyclic pyridone derivative | |
US6057340A (en) | Oxazole derivatives as serotonin-1A receptor agonists | |
US4771052A (en) | Tetrahydropyrido[3',4':4,5]pyrrolo[2,3-c]quinolines and their use as hypotensive agents | |
WO2007138343A1 (en) | N-phenylamidines as 5-ht2a receptor antagonists | |
AU662730B2 (en) | Neuroprotectant agents | |
WO2003033477A1 (en) | Alkynlated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitor | |
US4880818A (en) | 1-Acyl-4-[1-(4-quinolinyl)-hydrazin-2-ylidene]piperidines and their use as hypotensive agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07733645 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07733645 Country of ref document: EP Kind code of ref document: A1 |